Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henriette Mersebach

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Frontiers of Hormone Research|September 17, 2005
Growth hormone and body compositionHenriette Mersebach, Ulla Feldt-Rasmussen
Ugeskrift for Laeger|April 18, 2002
[Localized lipohypertrophy during growth hormone therapy]Henriette Mersebach, Ulla F Feldt-Rasmussen
The Journal of Clinical Endocrinology and Metabolism|December 13, 2003
Abnormal sympathoadrenal activity, but normal energy expenditure in hypopituitarismHenriette Mersebach, Ole Lander Svendsen, Arne Astrup, et al.
Plos One|October 21, 2016
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled TrialAjay Kumar, Edward Franek, Jonathan Wise, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 10, 2011
Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized studyLuigi Meneghini, Henriette Mersebach, Sudhesh Kumar, et al.
Obesity Research|December 17, 2004
Combined dietary and pharmacological weight management in obese hypopituitary patientsHenriette Mersebach, Marianne Klose, Ole L Svendsen, et al.
Journal of Diabetes Science and Technology|October 16, 2013
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialAndreas Liebl, Jaime Davidson, Henriette Mersebach, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 30, 2015
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALSDaniel Einhorn, Yehuda Handelsman, Bruce W Bode, et al.
Drugs & Aging|October 31, 2013
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trialsChristopher Sorli, Mark Warren, David Oyer, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|May 22, 2013
Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimesterPeter Damm, Henriette Mersebach, Jacob Råstam, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Frontiers of Hormone Research|September 17, 2005
Growth hormone and body compositionHenriette Mersebach, Ulla Feldt-Rasmussen
Ugeskrift for Laeger|April 18, 2002
[Localized lipohypertrophy during growth hormone therapy]Henriette Mersebach, Ulla F Feldt-Rasmussen
The Journal of Clinical Endocrinology and Metabolism|December 13, 2003
Abnormal sympathoadrenal activity, but normal energy expenditure in hypopituitarismHenriette Mersebach, Ole Lander Svendsen, Arne Astrup, et al.
Plos One|October 21, 2016
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled TrialAjay Kumar, Edward Franek, Jonathan Wise, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 10, 2011
Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized studyLuigi Meneghini, Henriette Mersebach, Sudhesh Kumar, et al.
Obesity Research|December 17, 2004
Combined dietary and pharmacological weight management in obese hypopituitary patientsHenriette Mersebach, Marianne Klose, Ole L Svendsen, et al.
Journal of Diabetes Science and Technology|October 16, 2013
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialAndreas Liebl, Jaime Davidson, Henriette Mersebach, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 30, 2015
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALSDaniel Einhorn, Yehuda Handelsman, Bruce W Bode, et al.
Drugs & Aging|October 31, 2013
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trialsChristopher Sorli, Mark Warren, David Oyer, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|May 22, 2013
Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimesterPeter Damm, Henriette Mersebach, Jacob Råstam, et al.
Pageof 2